Russell Cohen (University of Chicago Medicine, Chicago, IL, US) spoke with touchIMMUNOLOGY around the optimal use of available therapies in the treatment of IBD. ‘Positioning Tofacitinib and Other Available Therapies’ was presented at the virtual 2021 Crohn’s & Colitis Congress, 21-24 January, 2021.
- Could you tell us a little about tofacitinib and its available formulations? (0:15)
- What key messages would you like to give to physicians regarding the optimal use of tofacitinib in the treatment of IBD? (0:57)
- What other JAK inhibitors are available or in clinical development for IBD? (1:56)
- What is the current status of S1P1 inhibitors in IBD and in which patients should they be considered? (2:54)
- Could you tell us a little about aprelimast and the potential of anti-phosphodiesterase therapy in IBD? (4:20)
Disclosures: Speaker’s Bureau for Abbvie and Takeda; Consultant / Advisory/ Scientific Advisory Board for Abbvie Laboratories, BMS/ Celgene, Eli Lilly, Gilead Sciences, Janssen, Pfizer, Takeda and UCB Pharma; Clinical Trials /Grants (Principal Investigator; active) for Abbvie, BMS/Celgene, Boehringer Ingelheim, Crohn’s & Colitis Foundation of America, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast Ltd., Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, and UCB Pharma.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of CCC 2021 (Virtual).
Share this Video
Related Videos In Inflammatory Bowel Disease
Eamonn Quigley, DDW 2021: Biotherapeutic Blautia Hydrogentrophica in IBS
It was a pleasure to speak with Prof. Eamonn Quigley (Houston Methodist Hospital, Houston, TX, USA) about the phase 2 study of the single-strain live biotherapeutic, Blautia hydrogentrophica (Blautix), currently under investigation in irritable bowel syndrome (IBS). His abstract entitled ‘A Phase 2 Study of Live Biotherapeutic Blautix in Irritable Bowel Syndrome (IBS) Patients with […]
Stefan Schreiber, DDW 2021: Phase 2b/3 SELECTION and Long Term Extension Study Results
It was a pleasure to meet with Prof. Stefan Schreiber (Department of Internal Medicine, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany) to discuss the results from the Phase 2b/3 SELECTION and Phase 3 SELECTION long term extension study, investigating filgotinib for the treatment of ulcerative colitis. The abstract entitled ‘133: SAFETY ANALYSIS […]
Stefan Schreiber, DDW 2021: True North Study Results
It was a pleasure to meet with Prof. Stefan Schreiber (Department of Internal Medicine, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany) to discuss the results from the maintenance phase of the True North study, investigating corticosteroid free remission in patients with ulcerative colitis treated with ozanimod. The abstract entitled ‘142: CORTICOSTEROID-FREE REMISSION […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!